MannKind Q4 revenue $112M (+46% YoY); Furoscix adds $23M in first quarter

MANNKIND CORP

2025-FY EPS reported $0.02 revenue$348,966,000

Total revenues $112M in Q4 2025, up 46% vs Q4 2024; full-year revenues $349M, up 22%.
Afrezza net sales $23M in Q4, +25% YoY; Furoscix net sales $23M since acquisition Oct 7, 2025.
PDUFA target dates: Afrezza pediatric sBLA May 29, 2026; Furoscix ReadyFlow sNDA July 26, 2026.
R&D expense $27.6M (+148% YoY); SG&A $58.4M (+144%) driven by Furoscix and launch prep.
Cash & investments $176M at Dec 31, 2025; scPharmaceuticals acquisition completed Oct 7.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.